A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

Disclosed are compositions comprising nicotinamide riboside and a urolithin. The compositions are useful as medicaments, for example, for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases, and as dietary supplements, functional foods and beverages, and as specialized nutrition or medical foods.

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

The present invention relates to a composition comprising long chain polyunsaturated fatty acids (LC-PUFA) and ferrous sulphate monohydrate. Ferrous sulphate monohydrate advantageously does not cause significant oxidation of LC-PUFAs.

The present invention relates to a composition comprising long chain polyunsaturated fatty acids (LC-PUFA) and ferrous sulphate monohydrate. Ferrous sulphate monohydrate advantageously does not cause significant oxidation of LC-PUFAs.

The present invention relates to a composition for enhancing immunity or a composition for preventing or ameliorating neurodegenerative diseases, both of which contain, as an active ingredient, a mixture extract of goji berries, mulberries and jujubes or an extract mixture thereof.

One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.